ArticleClinical case reports2025
Haloperidol Induced Orofacial Dyskinesia: Clinical Insights Into Buccolingual Masticatory Syndrome.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Haloperidol Induced Orofacial Dyskinesia: Clinical Insights Into Buccolingual Masticatory Syndrome.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Haloperidol and other antipsychotics can cause buccolingual masticatory syndrome (BLMS), a rare but serious extrapyramidal disorder characterized by involuntary movements of the cheeks, jaws, and tongue. The author describes a 40-year-old man presenting with retrograde lingual movements, chewing difficulties, and speech impairment after 2 years of haloperidol therapy for catatonic-type schizophreniform disorder. Magnetic resonance imaging showed abnormal activity in the basal ganglia without structural lesions. Treatment with oral trihexyphenidyl hydrochloride, 5 mg daily, resulted in symptom resolution within 24 h. Haloperidol induces motor dysfunction by blocking dopamine D2 receptors in the basal ganglia. Haloperidol was discontinued, and the patient was transitioned to clozapine, a second-generation antipsychotic with a lower risk of tardive dyskinesia. Clozapine was initiated at 12.5 mg daily and titrated to 50 mg daily over two weeks, following standard hematologic monitoring protocols. Early diagnosis and appropriate management, including medication adjustment and adjunctive therapy, are critical to optimizing outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.